187 related articles for article (PubMed ID: 15279176)
1. Neoadjuvant chemotherapy of breast cancer.
Garces CA; Cance WG
Am Surg; 2004 Jul; 70(7):565-9. PubMed ID: 15279176
[TBL] [Abstract][Full Text] [Related]
2. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
3. Evidence-based use of neoadjuvant taxane in operable and inoperable breast cancer.
Estévez LG; Gradishar WJ
Clin Cancer Res; 2004 May; 10(10):3249-61. PubMed ID: 15161677
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : long-term results from the University of Texas M. D. Anderson Cancer Center Study ID97-099.
Alvarez RH; Booser DJ; Cristofanilli M; Sahin AA; Strom EA; Guerra L; Kau SW; Gonzalez-Angulo AM; Hortobagyi GN; Valero V
Cancer; 2010 Mar; 116(5):1210-7. PubMed ID: 20082452
[TBL] [Abstract][Full Text] [Related]
5. Phase III trial evaluating the addition of paclitaxel to doxorubicin followed by cyclophosphamide, methotrexate, and fluorouracil, as adjuvant or primary systemic therapy: European Cooperative Trial in Operable Breast Cancer.
Gianni L; Baselga J; Eiermann W; Porta VG; Semiglazov V; Lluch A; Zambetti M; Sabadell D; Raab G; Cussac AL; Bozhok A; Martinez-Agulló A; Greco M; Byakhov M; Lopez JJ; Mansutti M; Valagussa P; Bonadonna G
J Clin Oncol; 2009 May; 27(15):2474-81. PubMed ID: 19332727
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.
Fujii T; Le Du F; Xiao L; Kogawa T; Barcenas CH; Alvarez RH; Valero V; Shen Y; Ueno NT
JAMA Oncol; 2015 Dec; 1(9):1311-8. PubMed ID: 26402167
[TBL] [Abstract][Full Text] [Related]
7. [Primary systemic chemotherapy for breast cancer].
Takada M; Toi M
Gan To Kagaku Ryoho; 2007 Nov; 34(11):1730-4. PubMed ID: 18030005
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of primary systemic chemotherapy regimen containing anthracyclines with/without taxanes in comparison to CMF in women with early breast cancer.
Gschwantler-Kaulich D; Fink-Retter A; Hudelist G; Bachrich T; Ledesma M; Ruecklinger E; Kubista E; Singer CF
J Chemother; 2007 Dec; 19(6):731-8. PubMed ID: 18230558
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant chemotherapy with sequential or concurrent anthracycline and docetaxel: Breast International Group 02-98 randomized trial.
Francis P; Crown J; Di Leo A; Buyse M; Balil A; Andersson M; Nordenskjöld B; Lang I; Jakesz R; Vorobiof D; Gutiérrez J; van Hazel G; Dolci S; Jamin S; Bendahmane B; Gelber RD; Goldhirsch A; Castiglione-Gertsch M; Piccart-Gebhart M;
J Natl Cancer Inst; 2008 Jan; 100(2):121-33. PubMed ID: 18182617
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy for local advanced breast cancer with stage IIIB.
Kim R; Osaki A; Tanabe K; Toge T
Oncol Rep; 2004 Jun; 11(6):1265-72. PubMed ID: 15138565
[TBL] [Abstract][Full Text] [Related]
11. Long-term outcome of neoadjuvant therapy for locally advanced breast carcinoma: effective clinical downstaging allows breast preservation and predicts outstanding local control and survival.
Cance WG; Carey LA; Calvo BF; Sartor C; Sawyer L; Moore DT; Rosenman J; Ollila DW; Graham M
Ann Surg; 2002 Sep; 236(3):295-302; discussion 302-3. PubMed ID: 12192316
[TBL] [Abstract][Full Text] [Related]
12. Tailoring neoadjuvant chemotherapy for locally advanced breast cancer: a historical prospective study.
Zer A; Rizel S; Braunstein R; Yerushalmi R; Hendler D; Neimann V; Cioreuru N; Sulkes A; Stemmer SM
Chemotherapy; 2012; 58(2):95-101. PubMed ID: 22377846
[TBL] [Abstract][Full Text] [Related]
13. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.
Gianni L; Eiermann W; Semiglazov V; Manikhas A; Lluch A; Tjulandin S; Zambetti M; Vazquez F; Byakhow M; Lichinitser M; Climent MA; Ciruelos E; Ojeda B; Mansutti M; Bozhok A; Baronio R; Feyereislova A; Barton C; Valagussa P; Baselga J
Lancet; 2010 Jan; 375(9712):377-84. PubMed ID: 20113825
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy in patients with locally advanced breast cancer: A pilot-observational study.
Dodiya HG; Brahmbhatt AP; Khatri PK; Kaushal AM; Vijay DG
J Cancer Res Ther; 2015; 11(3):612-6. PubMed ID: 26458590
[TBL] [Abstract][Full Text] [Related]
15. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
[TBL] [Abstract][Full Text] [Related]
16. The expanding role of epirubicin in the treatment of breast cancer.
Glück S
Cancer Control; 2002; 9(2 Suppl):16-27. PubMed ID: 11965227
[TBL] [Abstract][Full Text] [Related]
17. Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?
Perez EA
Curr Oncol Rep; 2003 Jan; 5(1):66-71. PubMed ID: 12493153
[TBL] [Abstract][Full Text] [Related]
18. Phase II randomized clinical trial evaluating neoadjuvant chemotherapy regimens with weekly paclitaxel or eribulin followed by doxorubicin and cyclophosphamide in women with locally advanced HER2-negative breast cancer: NSABP Foundation Study FB-9.
Abraham J; Robidoux A; Tan AR; Limentani S; Sturtz K; Shalaby I; Alcorn H; Buyse ME; Wolmark N; Jacobs SA
Breast Cancer Res Treat; 2015 Jul; 152(2):399-405. PubMed ID: 26126970
[TBL] [Abstract][Full Text] [Related]
19. Effect of different neoadjuvant chemotherapy regimens on locally advanced breast cancer.
Coskun U; Gunel N; Onuk E; Yilmaz E; Bayram O; Yamac D; Cihan A; Ucan B; Yildirim Y; Celenkoglu G; Ozkan S
Neoplasma; 2003; 50(3):210-6. PubMed ID: 12937855
[TBL] [Abstract][Full Text] [Related]
20. Sequential or alternating doxorubicin and CMF regimens in breast cancer with more than three positive nodes. Ten-year results.
Bonadonna G; Zambetti M; Valagussa P
JAMA; 1995 Feb; 273(7):542-7. PubMed ID: 7837388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
